Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -1.78% is 100% above its 3-year average of -2640.73%, near the high end of its 3-year range (-32164.65%–70.90%).
99.93% above its 12-month average of -2413.51%.
Reported quarterly EBITDA margin; no daily interpolation. Q1 FY2025 (2025-03-31): 70.90%.
EBITDA MARGIN
-1.78%
EBITDA MARGIN AVG TTM
-2413.51%
EBITDA MARGIN AVG 3Y
-2640.73%
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+99.93%
CURRENT VS 3Y AVG
+99.93%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Century Therapeutics, Inc.
Market Cap
$239.02M
EBITDA Margin
-1.78%
TTM Avg
-2413.51%
3Y Avg
-2640.73%
5Y Avg
N/A
Market Cap
$237.57M
EBITDA Margin
-100.05%
TTM Avg
-392.29%
3Y Avg
-392.29%
5Y Avg
-392.29%
Market Cap
$236.82M
EBITDA Margin
-1029.09%
TTM Avg
-1029.09%
3Y Avg
-1029.09%
5Y Avg
-1029.09%
Market Cap
$241.34M
EBITDA Margin
-3813.88%
TTM Avg
-3607.01%
3Y Avg
-5701.50%
5Y Avg
-5701.50%
Market Cap
$241.39M
EBITDA Margin
32.18%
TTM Avg
32.18%
3Y Avg
-276.01%
5Y Avg
-1681.16%
Market Cap
$241.94M
EBITDA Margin
6.37%
TTM Avg
-0.39%
3Y Avg
-2.45%
5Y Avg
1.13%
Market Cap
$235.97M
EBITDA Margin
25.65%
TTM Avg
38.25%
3Y Avg
43.91%
5Y Avg
51.79%
Market Cap
$235.66M
EBITDA Margin
10.49%
TTM Avg
1.20%
3Y Avg
-4.19%
5Y Avg
-40.04%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | $239.02M | -1.78% | -2413.51% | -2640.73% | N/A |
| High Tide Inc. (HITI)vs › | $239.01M | 1.66% | 3.74% | -1.53% | 0.81% |
| Invivyd, Inc. (IVVD)vs › | $237.57M | -100.05% | -392.29% | -392.29% | -392.29% |
| BioAge Labs Inc. (BIOA)vs › | $236.82M | -1029.09% | -1029.09% | -1029.09% | -1029.09% |
| Quantum-Si incorporated (QSI)vs › | $241.34M | -3813.88% | -3607.01% | -5701.50% | -5701.50% |
| Q32 Bio Inc. (QTTB)vs › | $241.39M | 32.18% | 32.18% | -276.01% | -1681.16% |
| Lifecore Biomedical, Inc. (LFCR)vs › | $241.94M | 6.37% | -0.39% | -2.45% | 1.13% |
| SIGA Technologies, Inc. (SIGA)vs › | $235.97M | 25.65% | 38.25% | 43.91% | 51.79% |
| Akebia Therapeutics, Inc. (AKBA)vs › | $235.66M | 10.49% | 1.20% | -4.19% | -40.04% |
| Utah Medical Products, Inc. (UTMD)vs › | $235.08M | 37.26% | 38.63% | 43.69% | 46.28% |
Gross Margin
88.0%
EBITDA Margin
-1.8%
Operating Margin
-13.8%
Net Margin
-8.8%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2025-03-31 | 70.90% |
| 2024-12-31 | -813.95% |
| 2024-09-30 | -3981.16% |
| 2024-06-30 | -4058.75% |
| 2024-03-31 | -3284.56% |
| 2023-12-31 | -15003.73% |
| 2023-09-30 | -21808.11% |
| 2023-06-30 | -32164.65% |
| 2023-03-31 | -1739.01% |
| 2022-12-31 | -5743.38% |
| 2022-09-30 | -1302.34% |
| 2022-06-30 | -2126.29% |
| 2022-03-31 | -3428.73% |
